EGFR tyrosine kinase domain mutations in human gliomas.
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective in patients with lung cancer with mutations in exons 19 and 21 of the EGFR tyrosine kinase domain. In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, and low-grade gliomas. No mutation was found, which suggests that the biology of EGFR in gliomas is different from lung cancer and that this may be a factor in the resistance of glioblastomas to gefitinib.
Marie
Y
Y
Department of Neurology Mazarin and Institut National de la Santé et de la Recherche Médicale UMR-495, Paris, France.
Carpentier
A F
AF
Omuro
A M P
AM
Sanson
M
M
Thillet
J
J
Hoang-Xuan
K
K
Delattre
J-Y
JY
D001254:Astrocytoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D001932:Brain Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics*; D002277:Carcinoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics*; D000077156:Gefitinib; D005820:Genetic Testing; D005909:Glioblastoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D005910:Glioma / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D009154:Mutation / Q000235:genetics*; D009837:Oligodendroglioma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D017434:Protein Structure, Tertiary / Q000235:genetics; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib